Maximilian Merz

Dr. Maximilian Merz

1. Department of Hematology, Oncology and Rheumatology, University Hospital of Heidelberg, 69120 Heidelberg, Germany
+1

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MMMaximilian Merz
Maximilian Merz
JRJudith Ritsch
Judith Ritsch
CKChristina Kunz
Christina Kunz
BWBarbara Wagner
Barbara Wagner
SSSandra Sauer
Sandra Sauer
JHJens Hillengass
Jens Hillengass
Purpose: To noninvasively assess bone marrow microcirculation before and after therapy in patients with newly diagnosed multiple myeloma with dynamic contrast-enhanced MRI (DCE-MRI). Experimental Design: Ninety-six patients received DCE-MRI before and after primary treatment for newly diagnosed multiple myeloma. For the 91 evaluable patients, treatment consisted of high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) in 82 patients and chemotherapy without ASCT in 9 patients. In addition, 33 healthy volunteers were imaged as the control group. Analysis of DCE-MRI was performed according to the two-compartment model by Brix to quantify amplitude A (associated with blood volume) and exchange rate constant kep (reflecting vessel permeability and perfusion). Results: Nonresponders showed significantly higher A-values before the start of therapy compared with responders (P = 0.02). In both responders and nonresponders to therapy, A-values dropped significantly (P = 0.004 and <0.001, respectively) after primary therapy, whereas lower values for kep were found only in responders (P < 0.001). Depth of remission was significantly correlated to decreased bone marrow microcirculation: Patients in near complete response (nCR) or complete remission (CR) after treatment showed significantly lower values for A compared with patients not achieving nCR+CR. The application of HDT or novel agents had no significant effect on DCE-MRI parameters after therapy, although patients treated with novel agents more often achieved nCR+CR (42%/12.5%; P < 0.002). Higher kep-values at second MRI were positively correlated to shorter overall survival (HR 3.53; 95% confidence intervals, 1.21–10.33; P = 0.02). Conclusion: Parameters from DCE-MRI are correlated to remission after primary therapy and outcome in newly diagnosed multiple myeloma. Clin Cancer Res; 21(1); 106–12. ©2014 AACR.

29 July 2015 in European Radiology
Verified
Journal Article
Closed access
PDF file
MMMaximilian Merz
Maximilian Merz
TMThomas M. Moehler
Thomas M. Moehler
JRJudith Ritsch
Judith Ritsch
TBTobias Bäuerle
Tobias Bäuerle
CZChristian M. Zechmann
Christian M. Zechmann
JHJens Hillengass
Jens Hillengass

10 August 2016 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
MMMaximilian Merz
Maximilian Merz
THThomas Hielscher
Thomas Hielscher
ASAnja Seckinger
Anja Seckinger
DHDirk Hose
Dirk Hose
EMElias K. Mai
Elias K. Mai
JHJens Hillengass
Jens Hillengass
Deletion 17p13, del(17p), is associated with poor outcome in myeloma but some patients show long‐term survival. With the current study we intended to identify factors impacting outcome of such high risk patients. We analyzed 110 newly diagnosed, symptomatic patients with del(17p) detected by fluorescence in situ hybridization (FISH) in CD138‐purified myeloma cells to identify prognostic factors for survival. Age >65 years, ISS III, and elevated LDH negatively impacted survival. Patients with subclonal (10–60% of plasma cells) del(17p) had longer progression‐free survival (PFS) than patients with del(17p) in >60% of plasma cells (26 vs. 19 months, P = 0.03). Additional gain of 1q21 was associated with shorter PFS (17 vs. 25 months, P = 0.01). Hyperdiploidy did not ameliorate impact of del(17p), but gain 19q13 predicted longer PFS (30 vs. 18 months, P = 0.01) and overall survival (50 vs. 29 months, P = 0.01). Multivariate analysis in transplant eligible patients (≤65 years) revealed better survival for patients treated with upfront autologous transplantation (hazard ratio, [95% confidence interval]: 0.15 [0.04, 0.58], P = 0.006). Application of maintenance therapy was associated with better survival in transplant‐eligible patients (0.30 [0.09, 0.99], P = 0.05). We demonstrate heterogeneous outcome of patients with del(17p) according to baseline characteristics and treatment. 19q13 should be included in routine FISH panel, since gains were associated with better survival. Am. J. Hematol. 91:E473–E477, 2016.

11 November 2019 in Leukemia
Verified
Journal Article
Open access
PDF file
MMMaximilian Merz
Maximilian Merz
THThomas Hielscher
Thomas Hielscher
DSDavid Schult
David Schult
EMElias K. Mai
Elias K. Mai
MRMarc S. Raab
Marc S. Raab
HGHartmut Goldschmidt
Hartmut Goldschmidt

10 May 2016 in European Journal of Cancer
Verified
Journal Article
Closed access
PDF file
MMMaximilian Merz
Maximilian Merz
LJLina Jansen
Lina Jansen
FCFelipe A. Castro
Felipe A. Castro
JHJens Hillengass
Jens Hillengass
HSHans Salwender
Hans Salwender
HGHartmut Göldschmidt
Hartmut Göldschmidt

27 December 2017 in Blood Advances
Verified
Journal Article
Open access
PDF file
MMMaximilian Merz
Maximilian Merz
AJAnna Jauch
Anna Jauch
THThomas Hielscher
Thomas Hielscher
TBTilmann Bochtler
Tilmann Bochtler
SSStefan Olaf Schönland
Stefan Olaf Schönland
HGHartmut Goldschmidt
Hartmut Goldschmidt
Key Points: Clonal heterogeneity detected by iFISH is common in newly diagnosed MM. Treatment with bortezomib overcomes the negative impact of high-risk cytogenetic abnormalities if no further subclones are detected.